Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

December 26, 2022

To Shareholders,

Company Name: Renascience Inc.
Name of Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
Inquiries: Hiroyasu Ishimaru, Corporate Officer in charge of Administration and Corporate Planning

Notification of Regulatory Approval of Disposable Ultrafine Endoscope

The Company is pleased to announce that the disposable ultrafine endoscope has obtained regulatory approval (*1) from the Ministry of Health, Labour and Welfare (MHLW), which the Company has developed for noninvasive intraperitoneal observation in peritoneal dialysis (*2).

This product has been developed in collaboration with several universities including Tohoku University, St. Luke's International University, Juntendo University, and The Jikei University School of Medicine, with support from the Japan Agency for Medical Research and Development (AMED). The ultra-thin (approximately 1 mm in diameter) disposable endoscope can be inserted through a tube implanted in the peritoneum to inject dialysis fluid in peritoneal dialysis patients to observe the intra-abdominal cavity non-invasively. The product will be marketed by Baxter Limited, to which the Company has granted a license.

Peritoneal dialysis is a treatment for chronic renal failure that allows home care and has medical and economic advantages. Compared to hemodialysis (3 times a week, 4 hours each), home-based peritoneal dialysis treatment is less burdensome and ideal for patients. However, since the peritoneal membrane deteriorates over time and can cause serious complications in peritoneal dialysis, it is forced to discontinue in about five years. Currently, the only way to check the condition of the peritoneum is through laparotomy or observation with peritoneoscopy. This product allows non-invasive observation of the peritoneal cavity through an endoscope, facilitating diagnosis of complications and further improving the quality of life of peritoneal dialysis patients.

Details of this product are as follows

Approval Number: 30400BZX00294000
Japan Medical Device Nomenclature: Flexible laparoscope
Brand Name: Transcatheter laparoscopy PD VIEW

We will further work on the National Health Insurance (NHI) reimbursement (*3) and commercialization. The Company expects that the impact on the full-year business results for the fiscal year ending March 31, 2023 will be immaterial, but the Company will promptly announce any matters that should be disclosed in the future.

End

(*1) Regulatory approval: Approval by the Minister of Health, Labour and Welfare for the manufacture and sale of pharmaceuticals and medical devices, etc., based on the "Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices" (Act No. 145 of 1960, abbreviated as "Pharmaceuticals and Medical Devices Act" or "PMD Act"). The Pharmaceuticals and Medical Devices Agency (PMDA) examines the efficacy and safety of the product, and the Minister of Health, Labour and Welfare approves it after receiving a report from the Pharmaceutical Affairs and Food Sanitation Council.

(*2) Peritoneal dialysis: This method uses the peritoneum (a thin membrane covering the stomach, intestines, and other organs) of the body as a dialysis apparatus. When the abdominal cavity is filled with dialysis fluid through a tube (catheter), waste products in the blood, unnecessary urinary toxins, electrolytes, and excess water are transferred into the dialysis fluid to cleanse the blood.

(*3) NHI reimbursement: When a patient receives medical services at an insurance medical institution under the National Health Insurance system, the insurance medical institution charges a "health care fee" as compensation. The NHI reimbursement is shown as a "point" and the amount billed by the insurance is "technical fee + special treatment material fee + drug fee". Of this amount, the patient pays a portion (30% if the patient is of working age) at the reception of the medical institution. This system that allows patients to receive insured treatment is the NHI reimbursement.